Stocks · News reference
Piper Sandler analyst Biren Amin maintains LENZ Therapeutics (NASDAQ:LENZ) with a Neutral and lowers the price target from $12 to $7.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Gainers Dermata Therapeutics (NASDAQ:DRMA) stock moved upwards by 44.4% to $1.56 during Tuesday's after-market session. The company's market cap stands at $4.5 million. As per the news, the Q2 earnings report
Read original at benzingaLENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(1.02) per share which beat the analyst consensus estimate of $(1.06) by 3.77 percent. This is a 92.45 percent decrease over losses of $(0.53) per share from
Read original at benzinga